Evaxion Biotech A/S (NASDAQ:EVAX) Stock Price Down 2.9% – Should You Sell?

Evaxion Biotech A/S (NASDAQ:EVAX)’s stock price was down 2.9% on Friday . The company traded as low as $1.31 and last traded at $1.34. Approximately 14,835 shares were traded during trading, a decline of 93% from the average daily volume of 210,696 shares. The stock had previously closed at $1.38.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price target on shares of Evaxion Biotech A/S in a research note on Friday, November 1st.

Evaxion Biotech A/S Price Performance

The business has a 50 day simple moving average of $2.33 and a 200-day simple moving average of $2.84. The stock has a market cap of $7.86 million, a P/E ratio of -4.62 and a beta of -0.39. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00.

Evaxion Biotech A/S (NASDAQ:EVAX) last released its earnings results on Thursday, October 31st. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.08. The firm had revenue of $3.02 million during the quarter, compared to the consensus estimate of $0.19 million. On average, sell-side analysts forecast that Evaxion Biotech A/S will post -0.15 EPS for the current year.

Institutional Trading of Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Invst LLC bought a new position in Evaxion Biotech A/S (NASDAQ:EVAX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 54,000 shares of the company’s stock, valued at approximately $156,000. Invst LLC owned approximately 1.00% of Evaxion Biotech A/S as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 11.04% of the company’s stock.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.